SCHEMBL2994583

SCHEMBL2994583

CC1(N2CCC(Cc3ccc(Br)cc3Cl)C2=O)CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.36
OPRD1 P41143 1/20 0.34
LMNA P02545 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
ROCK2 O75116 1/20 0.33
RECQL P46063 1/20 0.33
HTR1A P08908 1/20 0.32
SLC6A4 P31645 1/20 0.32
PDE2A O00408 1/20 0.32
OPRM1 P35372 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993186 0.89 P2RX7 (0.40) P2RX7ALDH1A1KDM4EKMT2A
SCHEMBL3004507 0.79 PDE5A (0.40) ROCK2
SCHEMBL2989024 0.79 P2RX7 (0.41) P2RX7
Hydrochloric Acid SCHEMBL3878931 0.78 PDE5A (0.39) ROCK2
SCHEMBL2988985 0.78 P2RX7 (0.40) P2RX7
SCHEMBL2990822 0.77 HSD11B1 (0.54) P2RX7LMNANPSR1SMN1; SMN2ALDH1A1
SCHEMBL3004281 0.76 KMT2A (0.41) P2RX7LMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL4510092 0.76 HSD11B1 (0.38) P2RX7OPRD1OPRM1
SCHEMBL13674528 0.76 HSD11B1 (0.38) P2RX7OPRD1OPRM1
SCHEMBL2987020 0.75 ATM (0.41) P2RX7ALDH1A1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2010-07-22 US disclosed
US-7713979-B2 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-05-11 US disclosed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP disclosed
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 HSD11B1, HSDL2, HSD17B1 P2RX7 3884/4885OPRD1 324/4885LMNA 1510/4885
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD3B1 P2RX7 4250/4885OPRD1 201/4885LMNA 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.